Control Bionics Secures FDA Registration for NeuroStrip Wearable Platform

Control Bionics (ASX: CBL) has registered and listed its NeuroStrip surface electromyography wearable platform with the US Food and Drug Administration as a medical device.

Control Bionics expects the medical-grade credential to strengthen NeuroStrip’s positioning with advanced clinical rehabilitation providers, medical research institutions, and prospective human-computer interface and medtech development partners.

The company views the FDA registration as a step towards accelerating growth across NeuroStrip’s three application areas of Performance, Rehabilitation, and Research & Data.

The registration is not required for NeuroStrip’s existing use in sports performance and general rehabilitation, but adds regulatory stature to commercial discussions with existing and prospective customers across its target markets.

Broader Market Reach

NeuroStrip forms part of Control Bionics’ non-invasive neural-signal technology platform, which captures physiological signals including electrical activity generated by muscles and converts them into measurable outcomes.

The company has submitted further applications for registration with Australia’s Therapeutic Goods Administration (TGA), CE marking under the European Union (EU) Medical Device Regulation (MDR), and registration under the United Kingdom (UK) MDR framework.

Those pending applications form part of a broader regulatory strategy intended to support NeuroStrip’s expansion into new markets and deeper adoption with existing partners across multiple application settings.

The underlying platform serves Performance, Rehabilitation, Research & Data and Assistive Communication applications, extending technology historically used in Assistive Communication into sports performance, medical research, platform partnerships, and broader human-computer interface uses.

Medical Status Benefits

The FDA listing is expected to be particularly relevant where prospective customers and partners regard recognised US regulatory status as a baseline requirement for engagement.

“Formal recognition under the US medical device framework meaningfully strengthens our position in advanced clinical rehabilitation, medical research and future human-computer interface applications, where customers and partners expect a recognised regulatory foundation,” chief executive officer Jeremy Steele said.

“This registration builds on our 25 year plus legacy as an innovative medtech business and supports our strategy to accelerate growth across all three NeuroStrip application areas.”

“Combined with our pending TGA, CE and UK MDR applications, it reflects the breadth of our regulatory strategy as we continue to scale NeuroStrip into new markets and deepen adoption with existing partners.”